세계의 자궁내막증 시장 규모 조사 : 유형별, 치료별, 투여 경로별, 최종 사용자별, 유통 채널별, 지역별 예측(2022-2032년)

The Global Endometriosis Market is valued at approximately USD 1.22 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.0% over the forecast period 2024-2032. Endometriosis is a chronic medical condition where tissue similar to the lining inside the uterus, called the endometrium, grows outside the uterus. This abnormal growth can occur on the ovaries, fallopian tubes, outer surface of the uterus, and other pelvic organs. Endometriosis can cause significant pain, especially during menstrual periods, and may lead to fertility problems. The endometriosis market is undergoing significant transformation, driven by an increasing emphasis on women's health issues and the introduction of innovative treatments designed to alleviate the suffering associated with this condition. The heightened awareness among women worldwide about their condition and the increasing vocalization regarding their health issues are contributing to the market's growth, making it both highly profitable and significant.

The increasing prevalence of endometriosis has led to greater patient awareness and a shift in research and development focus towards improving treatment options. Government investments in healthcare infrastructure are further propelling the demand for drugs and diagnostic equipment for endometriosis treatment. High-priced hormone-based therapeutics dominate the market, with companies offering patient assistance programs to reduce the cost burden on patients. This approach is expected to drive patient adherence and market growth over the forecast period. However, the market faces challenges due to the lack of non-invasive diagnostic tests for endometriosis, which restrains its growth. The fear associated with non-invasive diagnostics procedures also poses a challenge, despite increasing awareness about early detection.

Key regions considered in the study include North America, Europe, Asia Pacific, Latin America, and the Rest of the World. Asia Pacific dominates the market with the presence of numerous generic manufacturers and rising disposable incomes. Asia Pacific countries present significant opportunities for the life sciences industry, with nations like India and South Korea making strides to establish themselves as major biopharmaceutical innovation hubs. The growing demand for curative treatments for life-threatening diseases emphasizes the importance of drug research and development, thereby driving the demand for related diagnostic and treatment solutions. North America holds the fastest market growth share due to its established regulatory framework, high demand for disease-specific treatment, and advanced healthcare infrastructure. Europe follows closely, driven by the presence of globally marketed players and population growth.

Major market players included in this report are:

• Pfizer Inc.
• Johnson & Johnson Private Limited
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Merck & Co., Inc.
• Boehringer Ingelheim International GmbH
• Novartis AG
• GlaxoSmithKline plc
• Bayer AG
• AstraZeneca
• Eli Lilly and Company
• Astellas Pharma Inc.
• Bristol-Myers Squibb Company
• Almirall, S.A
• Cadila Pharmaceuticals

The detailed segments and sub-segment of the market are explained below:

By Type:

• Superficial Peritoneal Lesion
• Endometrioma
• Deeply Infiltrating Endometriosis
• Others

By Treatment:

• Pain Medication
• Hormone Birth Control
• Gonadotropin-releasing Hormone (GnRH) Analogues
• Aromatase Inhibitors
• Others

By Route of Administration:

• Oral
• Parenteral
• Others

By End Users:

• Hospitals
• Homecare
• Speciality Centres
• Others

By Distribution Channel:

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

By Region:

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• U.K.
• Italy
• Spain
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Endometriosis Market Executive Summary

• 1.1. Global Endometriosis Market Size & Forecast (2022- 2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Type
  • 1.3.2. By Treatment
  • 1.3.3. By Route of Administration
  • 1.3.4. By End Users
  • 1.3.5. By Distribution Channel
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Endometriosis Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Endometriosis Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Rising Prevalence of Endometriosis
  • 3.1.2. Increased Awareness and Demand for Better Treatment Options
• 3.2. Market Challenges
  • 3.2.1. Lack of Non-invasive Diagnostic Tests
  • 3.2.2. High Costs of Treatment
• 3.3. Market Opportunities
  • 3.3.1. Growth in Biopharmaceutical Innovation Hubs
  • 3.3.2. Expansion of End-Use Industries

Chapter 4. Global Endometriosis Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top investment opportunity
• 4.4. Top winning strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Endometriosis Market Size & Forecasts by Type 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global Endometriosis Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 5.2.1. Superficial Peritoneal Lesion
  • 5.2.2. Endometrioma
  • 5.2.3. Deeply Infiltrating Endometriosis
  • 5.2.4. Others

Chapter 6. Global Endometriosis Market Size & Forecasts by Treatment 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global Endometriosis Market: Treatment Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 6.2.1. Pain Medication
  • 6.2.2. Hormone Birth Control
  • 6.2.3. Gonadotropin-releasing Hormone (GnRH) Analogues
  • 6.2.4. Aromatase Inhibitors
  • 6.2.5. Others

Chapter 7. Global Endometriosis Market Size & Forecasts by Route of Administration 2022-2032

• 7.1. Segment Dashboard
• 7.2. Global Endometriosis Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 7.2.1. Oral
  • 7.2.2. Parenteral
  • 7.2.3. Others

Chapter 8. Global Endometriosis Market Size & Forecasts by End-Users 2022-2032

• 8.1. Segment Dashboard
• 8.2. Global Endometriosis Market: End-Users Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 8.2.1. Hospitals
  • 8.2.2. Homecare
  • 8.2.3. Speciality Centres
  • 8.2.4. Others

Chapter 9. Global Endometriosis Market Size & Forecasts by Distribution Channel 2022-2032

• 9.1. Segment Dashboard
• 9.2. Global Endometriosis Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 9.2.1. Hospital Pharmacy
  • 9.2.2. Online Pharmacy
  • 9.2.3. Retail Pharmacy

Chapter 10. Global Endometriosis Market Size & Forecasts by Region 2022-2032

• 10.1. North America Endometriosis Market
  • 10.1.1. U.S. Endometriosis Market
    • 10.1.1.1. Type breakdown size & forecasts, 2022-2032
    • 10.1.1.2. Treatment breakdown size & forecasts, 2022-2032
  • 10.1.2. Canada Endometriosis Market
• 10.2. Europe Endometriosis Market
  • 10.2.1. U.K. Endometriosis Market
  • 10.2.2. Germany Endometriosis Market
  • 10.2.3. France Endometriosis Market
  • 10.2.4. Spain Endometriosis Market
  • 10.2.5. Italy Endometriosis Market
  • 10.2.6. Rest of Europe Endometriosis Market
• 10.3. Asia-Pacific Endometriosis Market
  • 10.3.1. China Endometriosis Market
  • 10.3.2. India Endometriosis Market
  • 10.3.3. Japan Endometriosis Market
  • 10.3.4. Australia Endometriosis Market
  • 10.3.5. South Korea Endometriosis Market
  • 10.3.6. Rest of Asia Pacific Endometriosis Market
• 10.4. Latin America Endometriosis Market
  • 10.4.1. Brazil Endometriosis Market
  • 10.4.2. Mexico Endometriosis Market
  • 10.4.3. Rest of Latin America Endometriosis Market
• 10.5. Middle East & Africa Endometriosis Market
  • 10.5.1. Saudi Arabia Endometriosis Market
  • 10.5.2. South Africa Endometriosis Market
  • 10.5.3. Rest of Middle East & Africa Endometriosis Market

Chapter 11. Competitive Intelligence

• 11.1. Key Company SWOT Analysis
• 11.2. Top Market Strategies
• 11.3. Company Profiles
  • 11.3.1. Pfizer Inc.
    • 11.3.1.1. Key Information
    • 11.3.1.2. Overview
    • 11.3.1.3. Financial (Subject to Data Availability)
    • 11.3.1.4. Product Summary
    • 11.3.1.5. Market Strategies
  • 11.3.2. Johnson & Johnson Private Limited
  • 11.3.3. Teva Pharmaceutical Industries Ltd.
  • 11.3.4. Sanofi
  • 11.3.5. Merck & Co., Inc.
  • 11.3.6. Boehringer Ingelheim International GmbH
  • 11.3.7. Novartis AG
  • 11.3.8. GlaxoSmithKline plc
  • 11.3.9. Bayer AG
  • 11.3.10. AstraZeneca
  • 11.3.11. Eli Lilly and Company
  • 11.3.12. Astellas Pharma Inc.
  • 11.3.13. Bristol-Myers Squibb Company
  • 11.3.14. Almirall, S.A
  • 11.3.15. Cadila Pharmaceuticals

Chapter 12. Research Process

• 12.1. Research Process
  • 12.1.1. Data Mining
  • 12.1.2. Analysis
  • 12.1.3. Market Estimation
  • 12.1.4. Validation
  • 12.1.5. Publishing
• 12.2. Research Attributes